This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Oral capecitabine was compared with intravenous bolus 5-fluorouracil and leucovorin, as adjuvant therapy.
Location/setting
Taiwan/secondary and tertiary care.
Methods

Analytical approach:
The analysis was based on a health-state transition model, with three main discrete disease states: stable disease, progressive disease, and death. The five time horizons included the 24-week treatment period plus three, four, five, or 10 years, or lifetime. The model included a hypothetical cohort of 100 patients. The authors stated that the perspective was that of the Bureau of National Health Insurance (BNHI) in Taiwan.
Effectiveness data:
The effectiveness data came from a phase III study (the Xeloda in adjuvant colon cancer therapy, X-ACT, study) that compared capecitabine with 5-fluorouracil and leucovorin (Twelves, et al. 2005 , see 'Other Publications of Related Interest' below for bibliographic details). This provided estimates of the time spent in each health state for the hypothetical cohort using the partitioned survival of the clinical trial data and an intention-to-treat analysis. A lognormal distribution was used to extrapolate the clinical endpoints beyond the follow-up period, which was a median of 3.8 years.
Monetary benefit and utility valuations:
The utility values were from published literature. It was assumed that there was no difference in utility over the 24-week chemotherapy period between the two treatments. The authors divided the period after treatment into two sections (pre-relapse and post-relapse) to reflect the difference in utility.
Measure of benefit:
Benefit was measured in life-months and quality-adjusted life-months (QALMs). Future benefits were discounted at an annual rate of 3%.
